TrialInvestigational new drugs2013

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Christian Manegold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.